OBJECTIVE: Morbidly adherent placentation (MAP) is an increasingly common and high-risk complication associated with significant maternal and neonatal morbidity. Current imaging modalities are suboptimal in the accurate and timely diagnosis of MAP. Our aim was to create a novel non-invasive surrogate marker of MAP in early pregnancy. To this aim, we collect, morphologically profile, and enumerate circulating trophoblasts (cTB) in maternal blood using a nanotechnology-enabled microchip (i.e., NanoVelcro Chips) that isolates rare circulating cells to identify predictors of MAP. STUDY DESIGN: We prospectively recruited and pathologicallyconfirmed women with normal and abnormal placentation. We utilized NanoVelcro Chips to enrich rare cTBs in maternal blood. In conjunction with the use of fluorescent microscopy, multi-marker immunocytochemistry with anti-CK7, anti-CD45, and anti-HLAG, we classified and enumerated cTBs immobilized on NanoVelcro Chips. Inclusion criteria were singleton pregnancies with no suspected aneuploidy or fetal anomalies. Student's t-test was used for continuous variables and Fisher's exact test compared categorical variables. Receiver-operative characteristics (ROC) curves were calculated to determine the predictive value of cTB for MAP. RESULTS: 45 women were recruited (n¼12 accreta, n¼19 previa, n¼14 controls). Mean maternal age was 35.7-years (19-43) with a BMI of 26.9 kg/m 2 . We developed a cTB atlas of the cTB diversity and isolated cTBs with high-efficiency as early as 6-weeks' gestation. We demonstrate that cTB and fetal fraction (FF) from first-trimester cell-free DNA is correlated (r:-0.71, p¼0.002). As expected, FF correlated to BMI (r:0.72, p¼0.009). ROC curves demonstrate that the area under the curve (AUC) for cTB enumeration is sensitive and specific for MAP with cTB clusters (AUC: 0.80) and single cTBs (AUC: 0.67) through gestation. CONCLUSION: Circulating trophoblasts in maternal blood are associated with abnormal placentation. Detection and enumeration of cTBs in early pregnancy holds significant promise to augment MAP diagnostic paradigms. We aim to transition to a large-scale clinical trial helping to attenuate MAP-related morbidity and we believe NanoVelcro Chip rare-cell enrichment has the potential to be a very sensitive technology for MAP diagnosis. Samples from maternal and fetal circuits were collected at time intervals to determine the concentrations of adalimumab and M281 in the perfusion medium using a sandwich ELISA and MSD method, respectively. Antipyrine (AP 100 mg/ml) was added as a marker compound to account for inter-placental variations. The M/F transfer rates (TRf, %) were calculated from the ratio of the concentration of the test substance in the fetal perfusate at the end of the experiment/concentration of the test substance in the maternal perfusate at the start of the experiment. RESULTS: The (M/F) transfer rate of AP was >40% in all experiments, indicating high perfusion overlap between the maternal and fetal circuits. Under these experimental conditions, the average TRf of M281 was 0.002 AE 0.002% (n¼14), suggesting insignificant transfer of M281 across the placenta. The average TRf of adalimumab was 0.23 AE 0.21% (range 0.03 e 0.65%, n¼8), which was decreased significantly in the presence of M281 to 0.06 AE 0.01%, p<0.01 (range 0.05 to 0.08%, n¼5). This decrease was further observed to be independent of M281 concentration. CONCLUSION: Transfer of M281 across human placenta to the fetal circuit is minimal. M281 significantly decreased the transfer of adalimumab from maternal to fetal circuit. These findings support evaluation of M281 as a potential therapeutic agent for fetal and neonatal diseases caused by transplacental transfer of allo/auto-immune pathogenic IgG antibodies.
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